Osteopontin in patients with idiopathic pulmonary hypertension

Chest

Volumn 139, Issue 5, 2011, Pages 1010-1017

  Lorenzen, Johan M ^a   Nickel, Nils ^a   Krämer, Robert ^a   Golpon, Heiko ^a   Westerkamp, Volker ^a   Olsson, Karen M ^a   Haller, Hermann ^a   Hoeper, Marius M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; ENDOTHELIN RECEPTOR ANTAGONIST; OSTEOPONTIN; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN DERIVATIVE; URIC ACID;

ADULT; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART CATHETERIZATION; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SURVIVAL RATE; URIC ACID BLOOD LEVEL; WALKING;

EID: 79955751292     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-1146     Document Type: Article

References (44)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336(2):111-117. (Pubitemid 27020889)
2. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006;16(2):79-87. (Pubitemid 43247403)
3. Rangaswami H, Bulbule A, Kundu GC. JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. J Biol Chem. 2005;280(19):19381-19392. (Pubitemid 41379646)
4. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IκBα kinase-dependent nuclear factor κB-mediated promatrix metalloproteinase-9 activation. J Biol Chem. 2004;279(37):38921-38935. (Pubitemid 39296053)
5. O'Regan A, Berman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol. 2000;81(6):373-390. (Pubitemid 32291179)
6. Yokosaki Y, Tanaka K, Higashikawa F, Yamashita K, Eboshida A. Distinct structural requirements for binding of the integrins αvβ6, αvβ3, αvβ5, α5β1 and α9β1 to osteopontin. Matrix Biol. 2005;24(6):418-427. (Pubitemid 41765020)
7. 1 integrin-osteopontin interaction. Exp Cell Res. 2000;258(2):342-351.
8. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993;7(15):1475-1482. (Pubitemid 24003267)
9. Patarca R, Saavedra RA, Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol. 1993;13(3-4):225-246. (Pubitemid 2030713)
10. Yu XQ, Fan JM, Nikolic-Paterson DJ, et al. IL-1 up-regulates osteopontin expression in experimental crescentic glomerulonephritis in the rat. Am J Pathol. 1999;154(3):833-841. (Pubitemid 29122602)
11. Ricardo SD, Franzoni DF, Roesener CD, Crisman JM, Diamond JR. Angiotensinogen and AT(1) antisense inhibition of osteopontin translation in rat proximal tubular cells. Am J Physiol Renal Physiol. 2000;278(5):F708-F716.
12. Hullinger TG, Pan Q, Viswanathan HL, Somerman MJ. TGFβ and BMP-2 activation of the OPN promoter: roles of smadand hox-binding elements. Exp Cell Res. 2001;262(1):69-74. (Pubitemid 32989009)
13. Diamond JR, Kreisberg R, Evans R, Nguyen TA, Ricardo SD. Regulation of proximal tubular osteopontin in experimental hydronephrosis in the rat. Kidney Int. 1998;54(5):1501-1509. (Pubitemid 28502892)
14. Ashizawa N, Graf K, Do YS, et al. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest. 1996;98(10):2218-2227. (Pubitemid 26394194)
15. Takemoto M, Yokote K, Yamazaki M, et al. Enhanced expression of osteopontin by high glucose. Involvement of osteopontin in diabetic macroangiopathy. Ann N Y Acad Sci. 2000;902:357-363.
16. Sodhi CP, Phadke SA, Batlle D, Sahai A. Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. Am J Physiol Renal Physiol. 2001;280(4):F667-F674.
17. Gadeau AP, Campan M, Millet D, Candresse T, Desgranges C. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb. 1993;13(1):120-125. (Pubitemid 23021592)
18. Burke DL, Frid MG, Kunrath CL, et al. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol. 2009;297(2):L238-L250.
19. Hoshikawa Y, Nana-Sinkam P, Moore MD, et al. Hypoxia induces different genes in the lungs of rats compared with mice. Physiol Genomics. 2003;12(3):209-219. (Pubitemid 37139700)
20. Hoshikawa Y, Matsuda Y, Suzuki S, et al. Osteopontin may be responsible for pulmonary vascular remodeling. Chest. 2005;128(6 suppl):621S.
21. Rosenberg M, Zugck C, Nelles M, et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail. 2008;1(1):43-49.
22. Donati V, Boldrini L, Dell'Omodarme M, et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res. 2005;11(18):6459-6465. (Pubitemid 41338982)
23. Bramwell VH, Doig GS, Tuck AB, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res. 2006;12(11 Pt 1):3337-3343.
24. Szalay G, Sauter M, Haberland M, et al. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ Res. 2009;104(7):851-859.
25. Singh M, Foster CR, Dalal S, Singh K. Osteopontin: role in extracellular matrix deposition and myocardial remodeling post-MI. J Mol Cell Cardiol. 2010;48(3):538-543.
26. Tamura A, Shingai M, Aso N, Hazuku T, Nasu M. Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. Circ J. 2003;67(9):742-744. (Pubitemid 37071232)
27. Stawowy P, Blaschke F, Pfautsch P, et al. Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur J Heart Fail. 2002;4(2):139-146. (Pubitemid 34233499)
28. Schäfer S, Ellinghaus P, Janssen W, et al. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res. 2009;82(1):30-39.
29. Dupuis J. Endothelin-receptor antagonists in pulmonary hypertension. Lancet. 2001;358(9288):1113-1114. (Pubitemid 32971839)
30. Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J. 2008;32(1):198-209.
31. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008;31(4):891-901.
32. Souza R, Jardim C, Julio Cesar Fernandes C, Silveira Lapa M, Rabelo R, Humbert M. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med. 2007;101(1):69-75. (Pubitemid 44835241)
33. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009;361(9):868-877.
34. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417 734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2009;266(6):558-570.
35. Kempf T, Wollert KC. Growth-differentiation factor-15 in heart failure. Heart Fail Clin. 2009;5(4):537-547.
36. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol. 2004;43(5):764-770. (Pubitemid 38296473)
37. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res. 1994;74(2):214-224. (Pubitemid 24029153)
38. Liaw L, Lindner V, Schwartz SM, Chambers AF, Giachelli CM. Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res. 1995;77(4):665-672.
39. Liaw L, Skinner MP, Raines EW, et al. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 1995;95(2):713-724.
40. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. NF-κB mediates αvβ3 integrin-induced endothelial cell survival. J Cell Biol. 1998;141(4):1083-1093. (Pubitemid 28243974)
41. Weintraub AS, Giachelli CM, Krauss RS, Almeida M, Taubman MB. Autocrine secretion of osteopontin by vascular smooth muscle cells regulates their adhesion to collagen gels. Am J Pathol. 1996;149(1):259-272. (Pubitemid 26230997)
42. Yoo KH, Thornhill BA, Forbes MS, et al. Osteopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction. Kidney Int. 2006;70(10):1735-1741.
43. Singh K, Sirokman G, Communal C, et al. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension. 1999;33(2):663-670. (Pubitemid 29091644)
44. Milting H, Ellinghaus P, Seewald M, et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant. 2008;27(6):589-596. (Pubitemid 351715387)